News
Market Data
Register for real-time alerts, custom portfolio, and market movers
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for c... Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier. Show more
Ask ADVFN Intelligence (AI)
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s Chief Executive Officer Norman...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on...
Acquisition of Emglev Therapeutics to focus on discovering single-domain antibodies (sdAbs) The VIO-01 trial is currently in Phase 1 dose escalation R&D efforts maintained for optimization...
Dell Technologies (NYSE:DELL), Palantir Technologies (NYSE:PLTR), Erie Indemnity (NASDAQ:ERIE), American Airlines (NASDAQ:AAL), Etsy (NASDAQ:ETSY), Bio-Rad Laboratories (NYSE:BIO) – S&P...
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK, Sept. 6, 2024 NEW YORK...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s Chief Executive Officer Norman...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.33 | -0.0904456503865 | 364.86 | 380.28 | 359.61 | 175717 | 371.20596587 | CS |
| 4 | 22.17 | 6.47563967753 | 342.36 | 380.28 | 319.57 | 199286 | 349.22249766 | CS |
| 12 | 36.64 | 11.1744792461 | 327.89 | 380.28 | 309.115 | 300228 | 334.48309859 | CS |
| 26 | 83.24 | 29.5922357709 | 281.29 | 380.28 | 262.01 | 274500 | 316.95619309 | CS |
| 52 | 63.22 | 20.9817131858 | 301.31 | 380.28 | 262.01 | 251227 | 315.57449434 | CS |
| 156 | -389.96 | -51.6852443372 | 754.49 | 784.39 | 261.59 | 216133 | 406.84301042 | CS |
| 260 | 14.32 | 4.08897518632 | 350.21 | 832.7 | 261.59 | 208153 | 449.38161327 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
